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Abstract
Background: Clozapine is the archetypical atypical antipsychotic, its primary indication being treatment resistant
schizophrenia. Severe side effects caused by clozapine, including leukopenia, agranulocytosis, and myocarditis, are
well known. A rarely described side effect is concurrent perimyocarditis and parenchymal lung disease.
Case presentation: A previously physically healthy 23-year-old male Caucasian that suffered from schizophrenia
presented with flu-like symptoms 1 week after starting clozapine treatment. Treatment with clozapine was
discontinued. He developed respiratory distress. Investigations showed significant parenchymal infiltration in both
of the lungs, pericardial fluid, and heart failure. He initially received treatment for suspected malignant neuroleptic
syndrome and later for suspected infection, but these tentative diagnoses were not confirmed. The patient’s
condition gradually improved. In retrospect, clozapine-induced parenchymal lung disease and perimyocarditis were
deemed the most probable causes.
Conclusions: Concurrent perimyocarditis and parenchymal lung disease are rare side effects of clozapine.
Clozapine-induced disease in general is considered an exclusion diagnosis. Lacking a verifiable diagnosis when
suspecting a side effect of clozapine, clinicians might treat the most likely and serious condition presenting and
consider discontinuing clozapine until the diagnostic uncertainty is reasonably resolved.
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Background
Clozapine is the archetypical atypical antipsychotic, its pri-
mary indication being treatment resistant schizophrenia.
The risk of leukopenia and agranulocytosis in clozapine
treatment is well established, affecting approximately 3.0
and 0.5% of patients, respectively [1, 2]. Accordingly, all
patients should routinely undertake blood samples.
Clozapine induced myocarditis is a recognized, though
perhaps overlooked, adverse effect of clozapine. Twenty
years ago the prevalence was estimated at less than
0.1%, but increased awareness and research has re-
vealed that the actual prevalence may be as high as
3.0% [3, 4]. The frequency of pericarditis caused by
clozapine is yet to be established and we are aware of
less than 10 cases that have been reported [5–7]. How-
ever, comorbid pericarditis and myocarditis precipitated
by the same aetiological factors (drugs, virus, ischemia,
etc.) and with common pathogeneses is not unusual.
Given the prevalence of clozapine-induced myocarditis,
the prevalence of pericarditis as an adverse effect of
clozapine might be higher than the number of pub-
lished case reports indicates. Clozapine-induced lung
disease seems to be exceptional, given the fact that only
a handful of cases have been published [8–10]. On the
other hand, there might be a lesson to learn from the
steady increase in reports of drug-induced lung disease
in general. In 1972, only 19 drugs were known to cause
lung disease [11]. Five years ago, the number had risen
to approximately 350, whereas today more than 600
drugs are recognized as potentially pneumotoxic [12].
In the early 1960s, the first reports of pulmonary
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damage caused by tricyclic antidepressants were pub-
lished, whereas today most psychotropic drugs are con-
sidered potentially pneumotoxic [13]. Case reports
serve important functions, including reporting new or
rare findings that may be of importance to clinicians
and others [14–16]. Treatment with clozapine can re-
sult in a myriad of side effects and symptoms, often
making clinical assessment difficult. This is even more
the case when several organ systems are involved and
the suspected conditions are considered highly infre-
quent. This case report demonstrates the challenges
facing clinicians in such a case.
Case presentation
A 23-year-old Caucasian man, diagnosed with schizo-
phrenia and without any prior history of cardiac or
pulmonary disease, was transferred from a psychiatric
ward to an intensive care unit with flu-like symptoms, i.e.,
fever (39.7–40.2 °C), nausea, non-productive cough, head-
ache, and muscle pain. The symptoms had developed
approximately 1 week after monotherapeutic clozapine-
treatment was initiated, and at the time of admittance the
daily dose was 300 mg. Initial blood sampling demon-
strated elevated levels of creatine kinase (2948 IU/L, range
50–400), C-reactive protein (154 mg/L, normal value <5),
lactate dehydrogenase (359 IU/L, range 105–205), aspar-
tate amino transferase (76 IU/L, range 15–45), erythrocyte
sedimentation rate (24 mm/h, normal value <13), and
myoglobin (248 μg/L, range <100), whereas white blood
cells were in the normal range (9.9 × 109/L, range 4–11).
Blood and urine cultures were negative. Saturation of per-
ipheral oxygen (SpO2) was 97%. Clinical examination re-
vealed an elevated systolic blood pressure (178/75 mmHg)
and tachycardia (120–130/min), but was otherwise nor-
mal, as were chest x-ray and electrocardiography (ECG).
The patient had no obvious mental symptoms or auto-
nomic instability. Despite the clinical picture being non-
characteristic, malignant neuroleptic syndrome was sus-
pected. Hence, clozapine was discontinued and treatment
with oral bromocriptine (a dopamine agonist) was com-
menced with a dose of 2.5 mg three times a day. Clinically,
the patient’s overall condition worsened in the next 24 h,
and he reported dyspnoea and respiratory-dependent
chest discomfort. Saturation of peripheral oxygen dropped
to 88%. Troponin T was now elevated (0.41 μg/L, normal
value < 0.03), as were fibrinogen (5.8 g/L, range 2–4), D-
dimer (3.7 FEUμg/mL, normal value <0.5), and white blood
cells (11.1 × 109/L), with a mild eosinophilia (0.46 × 109/L,
range 0.04–0.4). On the other hand, creatine kinase had
fallen (997 IU/L) and myoglobin had normalised (46 μg/L).
Extensive testing for various infectious agents, such as
streptococcus, coxsakcie A and B virus, Epstein-Barr virus,
adenovirus, influenza A and B virus, parainfluenza 1 and 3
virus, parvo B19 virus, mycoplasma pneumoniae,
chlamydia pneumoniae and cytomegalovirus, were under-
taken without any pathogen identified. Likewise, repeated
blood and urines cultures were negative. Given the fact
that the patient had been in intramural psychiatric care
for 2 months prior to the debut of his somatic symptoms,
causes like exposure to toxins, substance abuse and other
(prescribed or non-prescribed) drugs were believed to be
unlikely. At examination, the patient had tachycardia
(129–140/min), fever (39.7 °C) and prolonged exhalation
with crepitation and diminished respiratory sounds over
the lungs. The chest x-ray revealed significant parenchy-
mal infiltration in both lungs (Fig. 1).
Echocardiography depicted a left ventricular ejection
fraction of 54% (a.m. Simpson) and pericardial fluid.
Notwithstanding the lack of a demonstrable infective
agent and inconclusive blood samples, an infection was
presumed. Accordingly, malignant neuroleptic syndrome
was considered less likely. Thus, bromocriptine was
suspended and intravenous antibiotic treatment with a
cephalosporin, cefotaxime, started, with a daily dose of
6000 mg. The next couple of days there was little clinical
change, but troponin T (0.20 μg/L) and white blood cells
returned to normal, though still with a relative increase in
eosinophils: 3.02 and 3.54% at day 3 and 4, respectively,
compared to 0.50% the day before admittance and 0.56% at
the day of admittance. C-reactive protein remained high
(198–201 mg/mL). Echocardiography now exhibited biven-
tricular hypokinesia and dilatation with mitral and tricus-
pid valve insufficiency, a left ventricular ejection fraction of
34% (a.m. Simpson), and increased pericardial fluid. Chest
x-ray displayed regression of the parenchymal infiltration
in both lungs. In the following week, there was a gradual
improvement in the condition of the patient. The fever
dissipated, his breathing became unrestricted and subject-
ively the patient felt much better. Correspondingly, the
blood samples and chest x-rays normalized. Hence, after
8 days of treatment, the intravenous cephalosporin was
Fig. 1 Chest x-ray. Chest x-ray showing massive diffuse parenchymal
infiltration, predominantly of the left lung
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terminated and the patient transferred back to the psychi-
atric ward. Repeated follow-ups during the next 4 years
demonstrated blood samples within normal range and
chest x-rays without identifiable pathology. Echocardiogra-
phies, however, showed a persistent cardiomyopathy with
left ventricular hypokinesia and a left ventricular ejection
fraction (a.m. Simpson) of 42–45%.
Discussion
Adverse effects of clozapine can present with a multi-
tude of symptoms, thus mimicking a wide array of con-
ditions, as partially demonstrated by our case report.
Even serious side effects may have an insidious onset,
making early detection challenging. This is complicated
by the fact that the physical health of patients with severe
mental disorders often is poor, and comorbid somatic
conditions such as obstructive lung disease and cardiovas-
cular disease are common [17, 18]. At that, these patients
are less likely to report somatic symptoms [19]. As a
general rule, clozapine should always be suspected as a
potential culprit when a patient develops new or worsened
physical symptoms, in particular when the symptoms
point to a systemic process and appear in the early stages
of treatment. Most cases of myocarditis, pericarditis and
lung disease seem to develop within 2 to 3 weeks of com-
mencing clozapine [20]. It should also be taken into
account that the concomitant use of psychotropic drugs
adds to the risk of developing serious adverse effects, as
does comorbid metabolic syndrome, heart and lung
disease [21–25].
In this case, the diagnostic assessment was challenging.
Throughout the process, there was a certain level of
diagnostic doubt. Several diagnoses were deliberated,
clozapine-induced disease included. The latter, however,
has no pathognomonic clinical, biochemical, physical,
radiographic or histologic markers. In our case, the clini-
cians could not rule out an infection and consequently
chose the safer option: antibiotic treatment. Apparently,
the patient seemed to respond to this treatment, but
testing for an infection did not identify an infective agent.
In retrospect, we did a thorough clinical review of the case
in collaboration with cardiologists and pulmonologists. As
a result, parenchymal lung disease and perimyocarditis
were deemed the most likely diagnoses. Specifically, the
temporality of the drug treatment and the clinical devel-
opment, combined with the biochemical, radiological, and
echocardiographic findings strongly indicated adverse
effects of clozapine as causative. This hypothesis was
strengthened when the Naranjo Adverse Drug Reaction
Probability Scale estimated the causation as probable [26].
One lesson to take home from this case report might be
that clozapine-induced disease is an exclusion diagnosis.
Accordingly, lacking a verifiable diagnosis, the clinician
should treat the most likely and potentially dangerous
condition at any given moment, at the same time discon-
tinue clozapine until diagnostic uncertainty is reasonably
resolved.
Several investigations are relevant when suspecting a
clozapine-related lung and/or heart condition. Introducto-
rily, it should be noted that reports indicate that inflam-
mation may precipitate clozapine toxicity, possibly due to
a cytokine-mediated inhibition of cytochrome P450 1A2
[27]. Consequently, even moderate doses of clozapine
could produce significant increase in serum levels in the
presence of inflammation.
Elevated levels of C-reactive protein (incl. high-sensitivity
C-reactive protein), erythrocyte sedimentation rate and
plasma viscosity, are non-specific markers of inflammation.
So are white blood cells, but despite the dominant hypoth-
esis of a type I Ig E-mediated acute hypersensitivity reac-
tion, there is no specific level or pattern of white blood
cells signalling an adverse effect of clozapine. In other
words, eosinophilia, or any other white blood cell pattern,
may or may not be present [28]. On the other hand, the
presence of eosinophilia in peripheral blood does make the
diagnosis of a clozapine-related heart condition more
likely, as demonstrated in the majority of documented
cases [29]. Markers of myocardial damage such as myocar-
dial muscle creatine kinase, myoglobin and troponins may
be useful, but do not represent an unequivocal identifica-
tion of myocarditis, nor pericarditis. Troponins, for in-
stance, have a high specificity for myocardial damage, but
the sensitivity for acute myocarditis and pericarditis is
approximately 50 and 30%, respectively [30, 31].
Biopsy of heart and lung tissue may identify ongoing
inflammation, but sampling error and interobserver vari-
ability in sample interpretation remain significant limita-
tions to its diagnostic value. Furthermore, there is a
certain risk of complications [32–35]. Hence, biopsying
is not routinely undertaken when clozapine-triggered
disease is suspected, but may be necessary in order to
home in on the diagnosis. For instance, transbronchial
biopsy may aid in the diagnosis of other pulmonary dis-
eases such as pneumonia, sarcoidosis, etc. The same
goes for bronchoalveolar lavage. It is especially helpful in
differential diagnostics, primarily by excluding infective
aetiology to pulmonary infiltrates, secondarily to demon-
strate drug-induced eosinophilic pneumonia.
The ECG is widely used as a screening tool for cardiac
pathology, despite its low sensitivity.
There are no characteristic ECG patterns in myocardi-
tis and findings range from non-specific T-wave and ST-
segment changes, to ST-segment elevation mimicking
myocardial infarction, as well as supraventricular and
ventricular arrhythmias, QTc prolongation, abnormal
QRS configuration, etc. [36]. On the other hand, ECG,
as well as echocardiography, could be inconspicuous in
the presence of low-grade inflammation of the heart.
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Nevertheless, they are simple, low-risk procedures and
ECG is generally recommended as a standard procedure
before and during clozapine-treatment.
Cardiovascular magnetic resonance (CMR) enables
detection of various non-specific features of myocarditis
and pericarditis, though the sensitivity is variable, de-
pending on the level of damage [37]. Nevertheless, CMR
is preferable to chest x-ray and is the investigation of
choice when myocarditis is presumed. Chest x-ray is
typically obtained when drug-mediated pulmonary tox-
icity is suspected, but high-resolution computed tomog-
raphy (HR-CT) is more sensitive than chest radiography
for defining abnormalities [38, 39]. However, the sensi-
tivity is time-dependent and repeated HR-CTs may
therefore be necessary. For unknown reasons, HR-CT
was not performed in this particular case, which in hind-
sight should have been undertaken in order to clarify the
diagnosis. It is worth remembering that diffuse paren-
chymal lung changes is just one of many patterns that
drug-induced lung reactions may assume [40]. Hence,
radiological changes must be considered in conjunction
with anamnestic, clinical and investigative information
to determine the nature of pulmonary complications.
On pulmonary function tests, toxicity from most drugs
result in a restrictive lung disease pattern, with a de-
crease in total lung capacity. Despite being sensitive to
early changes in drug-induced lung function, these tests
are unspecific and provide limited diagnostic informa-
tion. Nonetheless, a pulmonary test could be useful in
monitoring treatment.
In summary, when faced with the possibility of clozapine
induced heart and/or lung disease, various and repeated
investigative procedures are needed to make a qualified
clinical assessment.
Conclusions
In treatment-resistant schizophrenia, clozapine is often
the drug of choice. However, the clinician should keep
in mind the drug’s potentially deleterious side effects.
Clozapine-induced diseases have no pathognomonic
features, initially often masquerading as innocent infec-
tions such as the common cold or the flu. Even severe
side effects might be difficult to pinpoint as clozapine re-
lated. In our case, the evidence of clozapine-induced
lung disease does not seem as strong as the evidence of
perimyocarditis. Besides discontinuing clozapine, no spe-
cific treatment has proven effective against adverse ef-
fects of clozapine. Thus, treatment is supportive and
symptom-oriented. Myocarditis is an important risk fac-
tor for cardiomyopathy. Hence, follow-up is mandatory
for all patients who have undergone myocarditis [41].
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